Sarah Hymowitz

Venture Partner at The Column Group

Dr. Hymowitz joined The Column Group in 2021 as a Venture Partner. Previously, she spent 22 years at Genentech rising to Vice President of Protein Sciences. In this role, she oversaw the large molecule drug discovery portfolio and mentored project teams on the identification and optimization of more than 35 clinical candidates. Earlier, as a member of the Genentech Small Molecule Leadership Team, she supported teams in advancing more than 25 molecules to IND-enabling studies and led a collaboration with AbbVie and the Walter and Eliza Hall Institute that resulted in the discovery of Venclexta. Dr. Hymowitz earned a B.A. in Chemistry from Swarthmore College, followed by a Ph.D. in Biophysics from the University of California, San Francisco prior to joining Genentech in 1999 as a postdoctoral fellow.

Location

San Francisco, United States

Links


Org chart

No direct reports

Teams


Offices


The Column Group

The Column Group (TCG) is a science-driven venture capital firm that makes significant financial and operational commitments to build early-stage drug discovery companies based on their unique scientific platforms and potential to deliver multiple breakthrough therapeutics.


Industries

Employees

11-50

Links